—–
The differential performance of polygenic risk scores (PRS) by population genetic background is a well-known scientific concern and one of the most important barriers to their equitable translation for clinical use. Not only must the social repercussions of how people are grouped for test development be considered, but the communication of their context specificity and differential performance to patients and their clinicians must be carefully managed. Drawing on recent research experiences with the development, validation, and implementation of PRS for common complex disease risk, this webinar will explore the scientific and ethical considerations relevant to the widespread adoption of PRS for clinical care.
Panelists:
Malia Fullerton, DPhil
University of Washington
Alicia Martin, PhD
Broad Institute
Moderator:
Alham Saadat, MS
Broad Institute, MIT, & Harvard University
Please join fellow audience members for an informal discussion in a Zoom meeting immediately following the forum. The link will be placed in the Zoom Chat during the forum. For those who cannot attend the live event, the forum will be recorded and archived on the ELSIhub Video page. Closed captioning will be provided for live and recorded events.
By registering for an ELSIhub event, attendees agree to abide by the ELSIhub Code of Conduct: https://elsihub.org/news/code-conduct